Similar to the results of another safety analysis study of SGLT2 inhibitors, the results of this study showed that the drug has a higher risk of non-spinal fracture, lower limb amputation, genital infection, diabetic ketoacidosis, hypovolemia, hypoglycemia, and severe UTIs, with similar risks; however, SGLT2 inhibitors have a lower risk of acute kidney injury (48). Here, SLC5A2 is linked to Hypoglycemia.